PL367891A1 - Kombinacja farmaceutyczna obejmująca albo kwas (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowy albo kwas 3-{4-[2-(4-tert-butoksykarbonyloaminofenylo) etoksy] fenylo}-(S)-2-etoksypropanowy oraz lek biguanidowy - Google Patents

Kombinacja farmaceutyczna obejmująca albo kwas (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowy albo kwas 3-{4-[2-(4-tert-butoksykarbonyloaminofenylo) etoksy] fenylo}-(S)-2-etoksypropanowy oraz lek biguanidowy

Info

Publication number: PL367891A1
Authority: PL; Poland
Prior art keywords: ethoxy; phenyl; propanoic acid; tert; pharmaceutical combination
Prior art date: 2001-06-01

Application number

PL02367891A

Other languages

English (en)

Inventor

Peter Öhman

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-01

Filing date

2002-05-30

Publication date

2005-03-07

2002-05-30 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-03-07 Publication of PL367891A1 publication Critical patent/PL367891A1/pl

Links

XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title abstract 2
229940123208 Biguanide Drugs 0.000 title abstract 2
229940079593 drug Drugs 0.000 title abstract 2
239000003814 drug Substances 0.000 title abstract 2
UCQVUNUTHKGDJR-NSHDSACASA-N (2s)-2-ethoxy-2-phenylpropanoic acid Chemical compound CCO[C@](C)(C(O)=O)C1=CC=CC=C1 UCQVUNUTHKGDJR-NSHDSACASA-N 0.000 title 1
-1 4-tert-butoxy carbonyl aminophenyl Chemical group 0.000 title 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
235000019260 propionic acid Nutrition 0.000 title 1
QNDFBOXBUCDYNZ-NRFANRHFSA-N (2s)-2-ethoxy-3-[4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 QNDFBOXBUCDYNZ-NRFANRHFSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

PL02367891A 2001-06-01 2002-05-30 Kombinacja farmaceutyczna obejmująca albo kwas (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowy albo kwas 3-{4-[2-(4-tert-butoksykarbonyloaminofenylo) etoksy] fenylo}-(S)-2-etoksypropanowy oraz lek biguanidowy PL367891A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0101980A SE0101980D0 (sv)	2001-06-01	2001-06-01	Pharmaceutical combination
PCT/SE2002/001038 WO2002096402A1 (en)	2001-06-01	2002-05-30	A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug

Publications (1)

Publication Number	Publication Date
PL367891A1 true PL367891A1 (pl)	2005-03-07

Family

ID=20284362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02367891A PL367891A1 (pl)	2001-06-01	2002-05-30	Kombinacja farmaceutyczna obejmująca albo kwas (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowy albo kwas 3-{4-[2-(4-tert-butoksykarbonyloaminofenylo) etoksy] fenylo}-(S)-2-etoksypropanowy oraz lek biguanidowy

Country Status (24)

Country	Link
US (1)	US20040152771A1 (pl)
EP (2)	EP1404309B1 (pl)
JP (1)	JP2004532864A (pl)
KR (1)	KR20040008202A (pl)
CN (1)	CN1535144A (pl)
AT (1)	ATE336993T1 (pl)
BR (1)	BR0210128A (pl)
CA (1)	CA2448643A1 (pl)
CO (1)	CO5540375A2 (pl)
CZ (1)	CZ20033234A3 (pl)
DE (1)	DE60214185T2 (pl)
EE (1)	EE200300584A (pl)
ES (1)	ES2269686T3 (pl)
HU (1)	HUP0400946A3 (pl)
IL (1)	IL159033A0 (pl)
IS (1)	IS7058A (pl)
MX (1)	MXPA03011005A (pl)
NO (1)	NO20035237D0 (pl)
PL (1)	PL367891A1 (pl)
RU (1)	RU2003136154A (pl)
SE (1)	SE0101980D0 (pl)
SK (1)	SK14702003A3 (pl)
WO (1)	WO2002096402A1 (pl)
ZA (1)	ZA200309264B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201513857A (zh) *	2013-07-05	2015-04-16	Cadila Healthcare Ltd	協同性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5783556A (en) *	1996-08-13	1998-07-21	Genentech, Inc.	Formulated insulin-containing composition
US6552055B2 (en) *	1996-12-11	2003-04-22	Dana-Farber Cancer Institute	Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6011049A (en) *	1997-02-19	2000-01-04	Warner-Lambert Company	Combinations for diabetes
SE9801992D0 (sv) *	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) *	1998-06-04	1998-06-04	Astra Ab	New 3-aryl propionic acid derivatives and analogs
ATE266409T1 (de) *	2000-04-13	2004-05-15	Pfizer Prod Inc	Synergistische wirkung von glyburide und milrinone

2001
- 2001-06-01 SE SE0101980A patent/SE0101980D0/xx unknown
2002
- 2002-05-30 AT AT02728300T patent/ATE336993T1/de not_active IP Right Cessation
- 2002-05-30 CZ CZ20033234A patent/CZ20033234A3/cs unknown
- 2002-05-30 PL PL02367891A patent/PL367891A1/pl not_active Application Discontinuation
- 2002-05-30 US US10/478,798 patent/US20040152771A1/en not_active Abandoned
- 2002-05-30 EP EP02728300A patent/EP1404309B1/en not_active Expired - Lifetime
- 2002-05-30 DE DE60214185T patent/DE60214185T2/de not_active Expired - Fee Related
- 2002-05-30 CN CNA028149394A patent/CN1535144A/zh active Pending
- 2002-05-30 MX MXPA03011005A patent/MXPA03011005A/es unknown
- 2002-05-30 KR KR10-2003-7015601A patent/KR20040008202A/ko not_active Withdrawn
- 2002-05-30 SK SK1470-2003A patent/SK14702003A3/sk not_active Application Discontinuation
- 2002-05-30 HU HU0400946A patent/HUP0400946A3/hu unknown
- 2002-05-30 BR BR0210128-9A patent/BR0210128A/pt not_active IP Right Cessation
- 2002-05-30 WO PCT/SE2002/001038 patent/WO2002096402A1/en not_active Ceased
- 2002-05-30 RU RU2003136154/15A patent/RU2003136154A/ru not_active Application Discontinuation
- 2002-05-30 CA CA002448643A patent/CA2448643A1/en not_active Abandoned
- 2002-05-30 EP EP06000170A patent/EP1666034A1/en not_active Withdrawn
- 2002-05-30 IL IL15903302A patent/IL159033A0/xx unknown
- 2002-05-30 JP JP2002592913A patent/JP2004532864A/ja not_active Withdrawn
- 2002-05-30 ES ES02728300T patent/ES2269686T3/es not_active Expired - Lifetime
- 2002-05-30 EE EEP200300584A patent/EE200300584A/xx unknown
2003
- 2003-11-25 NO NO20035237A patent/NO20035237D0/no not_active Application Discontinuation
- 2003-11-27 ZA ZA200309264A patent/ZA200309264B/en unknown
- 2003-11-28 IS IS7058A patent/IS7058A/is unknown
- 2003-12-23 CO CO03112108A patent/CO5540375A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
ATE336993T1 (de)	2006-09-15
HUP0400946A3 (en)	2007-11-28
NO20035237D0 (no)	2003-11-25
EP1404309A1 (en)	2004-04-07
WO2002096402A1 (en)	2002-12-05
EP1404309B1 (en)	2006-08-23
IS7058A (is)	2003-11-28
SK14702003A3 (sk)	2004-09-08
IL159033A0 (en)	2004-05-12
ZA200309264B (en)	2005-02-28
JP2004532864A (ja)	2004-10-28
CA2448643A1 (en)	2002-12-05
DE60214185T2 (de)	2007-07-19
BR0210128A (pt)	2004-06-08
CN1535144A (zh)	2004-10-06
MXPA03011005A (es)	2004-02-27
DE60214185D1 (en)	2006-10-05
HUP0400946A2 (hu)	2004-08-30
CO5540375A2 (es)	2005-07-29
RU2003136154A (ru)	2005-02-10
HK1062813A1 (en)	2004-11-26
ES2269686T3 (es)	2007-04-01
EE200300584A (et)	2004-02-16
US20040152771A1 (en)	2004-08-05
EP1666034A1 (en)	2006-06-07
CZ20033234A3 (cs)	2004-12-15
KR20040008202A (ko)	2004-01-28
SE0101980D0 (sv)	2001-06-01

Similar Documents

Publication	Publication Date	Title
BRPI0418200A (pt)	2007-04-17	forma cristalina do sal de 4-(3-cloro-4-(ciclopropilaminocarbonila) aminofenóxi)-7-metóxi-6-quinolinacarboxamida ou o solvato do sal e um processo para a sua preparação
CL2004001530S1 (es)	2005-04-15	Cartucho para hojas de afeitar de cuerpo superior rectangular de extremos semicirculares, con rebaje superficial de perfil similar y bordes concavos, y abertura central cercada frontalmente por un lomo entre dos filas de agujeros circulares y por dos
BR9910913A (pt)	2001-03-06	Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
HRP20090229T1 (en)	2009-05-31	Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
PL367891A1 (pl)	2005-03-07	Kombinacja farmaceutyczna obejmująca albo kwas (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowy albo kwas 3-{4-[2-(4-tert-butoksykarbonyloaminofenylo) etoksy] fenylo}-(S)-2-etoksypropanowy oraz lek biguanidowy
MXPA03011012A (es)	2004-02-27	Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina.
MXPA03011010A (es)	2004-02-27	Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoxi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil] propanoico o acido 3-{4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico y una sulfonilurea.
HK1062527A (en)	2004-11-12	A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
IS8224A (is)	2006-01-10	Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
IL172376A0 (en)	2009-02-11	Process for the preparation of racemic 2{[2-(4- hydroxyphenyl)ethyl]thio}-3-[4-(2-{4- [(methylsulphonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
NO20000665D0 (no)	2000-02-10	2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat
JP2000204075A5 (pl)	2006-04-27
ATE250600T1 (de)	2003-10-15	Optische spaltung von 1-azabicylo(2.2.2)octan-3- amin,2-(diphenylmethyl)-n-((2-methoxy-5-(1- methylethyl)phenyl)methyl)
BR0207867A (pt)	2004-03-23	Sal de benzoilguanidina
TW200503679A (en)	2005-02-01	Therapeutic agents
HK1087395A (en)	2006-10-13	Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio} -3-{4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
TH81759A (th)	2006-12-14	สารสำหรับใช้บำบัดโรค
NL1025691A1 (nl)	2004-09-14	Kristallijn S-[c2-[c(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteïne- maleaat-hydrochloride-zout.
JP2599292Y2 (ja)	1999-08-30	コンパクト容器
AR030731A1 (es)	2003-09-03	Nuevas formas de sales solidas de n-(2-(4-[2-(1-metiletoxi)fenil]-1-piperazinil]etil]-2-oxo-1-piperidinacetamida
DE60142063D1 (de)	2010-06-17	(2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propion säureisopropylester, dessen herstellung und dessen verwendung
KR950703579A (ko)	1995-09-20	우레이도아세트아미드 유도체, 그들의 제조 및 상기를 함유하는 약제(urei-do-acetamide derivatives, preparation thereof and drugs con-taining same)
HK1087396A (en)	2006-10-13	Potassium or sodium salt of (-)-2- {'2-(4-hydroxyphenyl)ethyl]-thio -3-'4-(2- {4-'(methylsulfonyl)oxy ]phenoxy }phenyl]propanoic acid and their use in medicine.
ATE302720T1 (de)	2005-09-15	Zusammenklappbarer kistenförmiger behälter
DK1387683T3 (da)	2005-06-06	Hidtil ukendte saltformer eller krystallinske former af (2R)-anti-5-3-[4-(10,11-difluormethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy quinolin

Legal Events

Date	Code	Title	Description
2010-01-29	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)